Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

Experimental Alzheimer’s Vaccine Shows Promise

Researchers have developed a tau-targeting vaccine that could help prevent the progression of Alzheimer’s disease by generating a strong immune response against abnormal tau proteins. The vaccine showed effectiveness in mice and non-human primates, prompting researchers to pursue human clinical trials.

Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease

Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer’s disease (AD). Clinical trials focused on cel…

GLP-1 Agonists and SGLT2 Inhibitors Considered More Effective for Lowering Alzheimer Disease Risk

The findings support the neuroprotective effects of GLP-1RAs and SGLT2is, suggesting their possible role in Alzheimer disease prevention strategies in people with type 2 diabetes.

The National Health Surveillance Agency (Anvisa) announced, this Tuesday, April 22, the approval of donanemabe, commercially known as Kisunla, a new drug aimed at treating Alzheimer's disease in the early stages. Clinical studies have indicated that the use of this drug may slow the progression of the disease by up to 35% in the least... The post Anvisa approves new drug for Alzheimer's appeared first on The Antagonist.

On Tuesday (April 22, 2025), Anvisa (the Brazilian Health Regulatory Agency) approved Kisunla, the first medication indicated for the treatment of mild cognitive impairment or mild dementia associated with early-stage Alzheimer's disease. The medication, manufactured in Brazil by Eli Lilly, has donanemab as its active ingredient. According to the agency, it is a “monoclonal antibody that binds to a protein called beta-amyloid”. Registration for…

Donanemabe is indicated for initial symptoms of the disease, which is the main form of dementia The National Sanitary Vigilance Agency (Anvisia) approved on this Wednesday (22) donanemabe, an independent treatment for Alzheimer. Marketingd under the name of Kisunla, the American medicine of Eli Lilly, is indicated for treatment for adults with initial symptoms of Alzheimer’s disease, which includes patients with mild cognitive compromise or low …